Nafarelin (Synarel) - Complete Research Paper

1. Summary

Nafarelin is a gonadotropin-releasing hormone (GnRH) agonist administered as a nasal spray for the treatment of endometriosis and central precocious puberty (CPP). Marketed under the brand name Synarel by Pfizer (originally developed by Syntex), nafarelin received FDA approval on February 13, 1990, making it the first new treatment for endometriosis to enter the U.S. market in 14 years. It was rated by the FDA as a "1B" drug, indicating therapeutic advantages over existing treatments.

Nafarelin is one of only two medically used GnRH analogs available as nasal sprays (the other being buserelin, which is not available in the US). This non-injection delivery system offers significant advantages for patients who are needle-averse, particularly children with CPP requiring long-term therapy.

The medication works through the characteristic GnRH agonist mechanism: initial stimulation of pituitary gonadotropin release followed by receptor downregulation and sustained suppression of the hypothalamic-pituitary-gonadal axis. This results in profound reduction of sex hormone levels to prepubertal (in CPP) or postmenopausal (in endometriosis) ranges.

For endometriosis, nafarelin provides pain relief and reduction of lesion size through estrogen suppression. For CPP, it arrests secondary sexual development, slows linear growth and skeletal maturation, and preserves adult height potential. Clinical trials demonstrated arrest or regression of breast development in 82% of girls and genital development in 100% of boys.

Standard dosing is 200 mcg (one spray) per nostril twice daily (400 mcg total for endometriosis) or escalated to 1800 mcg daily if needed for CPP. The nasal spray bioavailability is approximately 2.8%, requiring the higher microgram doses compared to injectable GnRH agonists. Effects are fully reversible, with normal pituitary-gonadal function typically restored within 4-8 weeks of discontinuation.

2. Mechanism of Action

Nafarelin is a synthetic decapeptide analog of naturally occurring gonadotropin-releasing hormone (GnRH). The molecule incorporates structural modifications that enhance receptor binding affinity and increase resistance to proteolytic degradation, providing extended biological activity compared to endogenous GnRH.

Initial Agonist Phase (Flare Effect): Upon administration, nafarelin binds to and continuously activates GnRH receptors on anterior pituitary gonadotroph cells:

Pituitary Response:

• Stimulation of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release
• Transient "flare" effect lasting 1-2 weeks
• May cause temporary worsening of pubertal signs in CPP

Gonadal Response:

• Transient increase in sex hormone production
• Girls: Breast enlargement, vaginal bleeding possible in first month
• Boys: Temporary increase in testosterone effects

Sustained Suppression Phase: Continuous GnRH receptor activation leads to profound desensitization:

Mechanism:

• GnRH receptor becomes non-functional through chronic stimulation
• Receptor internalization and downregulation
• Gonadotroph cells become refractory to GnRH stimulation
• "Chemical desensitization" of pituitary

Hormonal Consequences (by weeks 2-4):

• Suppression of LH and FSH secretion to prepubertal levels
• Estradiol suppression to prepubertal/postmenopausal levels
• Testosterone suppression to prepubertal levels in boys
• Cessation of gonadal steroid production

Therapeutic Effects:

Central Precocious Puberty:

• Arrests secondary sexual development
• Slows linear growth velocity
• Delays skeletal maturation (bone age advancement)
• Preserves adult height potential
• Fully reversible upon discontinuation

Endometriosis:

• Hypoestrogenic state induces atrophy of ectopic endometrial tissue
• Pain relief (dysmenorrhea, pelvic pain)
• Reduction in size and extent of endometriotic lesions
• Treatment limited to 6 months due to bone density effects

Note on Pubic Hair: Pubic hair growth is largely controlled by adrenal androgens, which are unaffected by nafarelin. Therefore, pubic hair development was arrested or regressed in only 54% of children, compared to 82-100% for other pubertal features.

Goal Archetype Integration

Primary Classification: Intranasal GnRH Agonist - Endometriosis / Central Precocious Puberty

Goal Archetype Mapping:

When This Compound Makes Sense

Endometriosis:

• Women seeking non-injection hormonal therapy for moderate-to-severe endometriosis pain
• Patients who have failed or cannot tolerate oral progestins (norethindrone) or NSAIDs
• Women desiring reversible hormonal suppression before attempting conception
• Patients preferring self-administered therapy over monthly clinic injections
• Those with needle phobia who still need GnRH agonist suppression

Central Precocious Puberty:

• Children with confirmed central (gonadotropin-dependent) precocious puberty
• Families preferring non-injection therapy for long-term pubertal suppression
• Cases where compliance with twice-daily nasal spray is expected to be good
• When avoiding injection-related trauma in young children is prioritized
• Patients without significant nasal conditions that would impair absorption

IVF/Assisted Reproduction (Off-Label):

• Women undergoing controlled ovarian hyperstimulation who prefer nasal administration
• IVF protocols requiring pituitary downregulation before gonadotropin stimulation

When to Choose Something Else

Choose Injectable GnRH Agonist (Leuprolide, Goserelin, Triptorelin) When:

• Compliance with twice-daily nasal dosing is a concern
• Chronic nasal conditions (rhinitis, sinusitis, polyps) may impair absorption
• Monthly or quarterly dosing is preferred for convenience
• Office-based administration ensures compliance

Choose GnRH Antagonist (Elagolix oral, Degarelix injectable) When:

• Flare avoidance is critical (not applicable for endometriosis/CPP indications)
• Oral daily therapy is preferred (elagolix for endometriosis)
• More immediate suppression onset is needed

Choose Alternative Endometriosis Therapies When:

• Mild symptoms: NSAIDs and combined oral contraceptives first
• Moderate symptoms: Progestins (norethindrone) or LNG-IUD first-line
• Bone density concerns preclude 6-month GnRH agonist course
• Patient desires continuous therapy beyond 6 months (add-back therapy required)

Choose Histrelin Implant (Supprelin LA) for CPP When:

• Annual dosing preferred over daily nasal administration
• Compliance with nasal spray is problematic
• Child has difficulty with nasal administration technique

Unique Value Proposition: Intranasal GnRH Agonist

Nafarelin's intranasal delivery system distinguishes it from all other GnRH agonists:

3. FDA-Approved Indications

Central Precocious Puberty (CPP):

• Treatment of gonadotropin-dependent precocious puberty in children of both sexes
• Diagnostic criteria: Premature secondary sexual development at or before age 8 in girls, age 9 in boys
• Must be accompanied by bone age advancement and/or poor adult height prediction
• Confirmation of central (hypothalamic-pituitary) origin required
• Treatment continues until appropriate age for natural puberty

Endometriosis:

• Management of endometriosis, including pain relief and reduction of endometriotic lesions
• Approved for women 18 years and older
• Treatment duration: Up to 6 months recommended
• First new endometriosis treatment in US in 14 years at approval

Off-Label Uses:

• Uterine fibroids (preoperative size reduction)
• In vitro fertilization (IVF) protocols (pituitary suppression)
• Premenopausal breast cancer (ovarian suppression)
• Transgender hormone therapy (puberty suppression)

Regulatory History:

• FDA approved: February 13, 1990
• Rating: "1B" (offers therapeutic advantages over existing treatments)
• First regulatory approval worldwide
• Currently marketed by Pfizer (G.D. Searle, LLC, Division of Pfizer, Inc.)

4. Dosing and Administration

Formulation:

• Synarel nasal spray: 2 mg/mL nafarelin acetate solution
• Each bottle: Approximately 60 metered sprays
• Each spray: 200 mcg nafarelin in 100 mcL solution
• Delivered intranasally

Endometriosis Dosing:

• Standard dose: 200 mcg (one spray) into one nostril in the morning and one spray into the other nostril in the evening
• Total daily dose: 400 mcg
• Alternative: 200 mcg into each nostril morning and evening (800 mcg/day) if amenorrhea not achieved
• Treatment duration: Recommended not to exceed 6 months
• Begin treatment between days 2-4 of menstrual cycle

Central Precocious Puberty Dosing:

• Starting dose: 1600 mcg/day
  • 400 mcg (two sprays) into alternating nostrils twice daily (morning and evening)
  • Or 200 mcg (one spray) into alternating nostrils three times daily
• If inadequate response at 2 months: Increase to 1800 mcg/day (600 mcg TID)
• Continue until appropriate age for natural puberty onset

Administration Technique:

1. Patient should be upright with head tilted slightly forward
2. Clear nasal passages before use
3. Prime pump before first use if new bottle
4. Insert spray tip into nostril
5. Spray while breathing in gently
6. Alternate nostrils for each dose
7. Avoid sneezing during or immediately after dosing (may impair absorption)

Important Considerations:

• Nasal decongestants: If required, use at least 2 hours after Synarel dosing
• Nasal congestion: May reduce absorption; monitor for adequate suppression
• Compliance: Critical for effectiveness; missed doses reduce efficacy
• Rhinitis: May affect drug delivery

Timing:

• Doses should be approximately 12 hours apart for BID dosing
• Regular timing important for consistent suppression

5. Pharmacokinetics

Absorption:

• Route: Intranasal (nasal mucosa absorption)
• Bioavailability: 2.8% (range 1.2-5.6%) from 400 mcg dose
• Rapidly absorbed into systemic circulation
• Time to peak concentration (Tmax): 10-40 minutes
• Peak concentration (Cmax):
  • 200 mcg dose: 0.6 ng/mL (range 0.2-1.4 ng/mL)
  • 400 mcg dose: 1.8 ng/mL (range 0.5-5.3 ng/mL)

Distribution:

• Plasma protein binding: 80%
• Primarily bound to albumin
• Distribution to pituitary gland (target organ)

Metabolism:

• Primary pathway: Peptidase degradation
• NOT metabolized by cytochrome P450 enzymes
• Six metabolites identified
• Major metabolite: Tyr-D(2)-Nal-Leu-Arg-Pro-Gly-NH2 (5-10 fragment)
• Metabolites are inactive

Elimination:

• Elimination half-life (intranasal): 2.5-3.0 hours
• Half-life including metabolites (subcutaneous): 85.5 hours
• Urinary excretion: 44-55% of dose
• Fecal excretion: 18.5-44.2% of dose
• Unchanged drug in urine: ~3%

Drug Interactions:

• No formal pharmacokinetic drug-drug interaction studies conducted
• Low probability of interactions due to:
  • Peptidase metabolism (not CYP450)
  • Only 80% protein binding
• No dose adjustments expected for concurrent medications

Special Populations:

• Pediatric: Pharmacokinetics similar to adults
• Renal impairment: No formal studies; caution advised
• Hepatic impairment: Non-hepatic metabolism; likely safe
• Nasal conditions: May reduce absorption; clinical monitoring essential

6. Side Effects and Adverse Reactions

Very Common (>10% incidence):

Hormonal Suppression Effects:

• Hot flashes/flushes: 60-90% (most common side effect)
• Decreased libido: 20-40%
• Vaginal dryness: 15-25%
• Headaches: 15-25%
• Mood changes: 15-25%

Nasal/Local Effects:

• Nasal irritation/rhinitis: 10-20%
• Nasal dryness: 5-15%

Initial Treatment Effects (First Month - CPP):

• Vaginal bleeding/spotting in girls: Variable
• Breast enlargement in girls: Expected to resolve after first month
• These represent initial flare before suppression

Common (1-10% incidence):

Neurological:

• Headache: 15-25%
• Dizziness: 3-6%

Psychiatric:

• Emotional lability: 5-15%
• Depression: 3-8%
• Mood swings: 5-10%
• Irritability: 5-10%

Musculoskeletal:

• Myalgia: 3-6%
• Arthralgia: 2-5%

Dermatological:

• Acne: 3-8%
• Seborrhea: 2-5%

Gastrointestinal:

• Nausea: 3-6%
• Weight changes: 3-8%

Serious Adverse Reactions:

Psychiatric Events (Pediatric CPP):

• Emotional lability including crying, irritability, impatience, anger, aggression
• Mood swings
• Depression
• Rare reports of suicidal ideation and suicide attempt in children
• Requires monitoring and appropriate intervention

Convulsions (Postmarketing):

• Reports with GnRH agonists including nafarelin
• Risk factors:
  • History of seizures or epilepsy
  • Cerebrovascular disorders
  • CNS anomalies or tumors
  • Concurrent medications (bupropion, SSRIs)
• Convulsions also reported without predisposing factors

Bone Mineral Density Loss:

• Progressive bone loss with prolonged therapy
• Limits endometriosis treatment to 6 months
• Less concern in pediatric CPP (bone accrual resumes after treatment)
• Consider bone protection for extended use

Allergic Reactions:

• Hypersensitivity reactions (rare)
• Anaphylaxis (very rare)
• Skin rashes

Ovarian Cysts (Endometriosis):

• May develop during first 2 months
• Usually resolve spontaneously
• Rarely require intervention

7. Drug Interactions

No Significant Drug Interactions Expected:

Pharmacokinetic Basis:

• Nafarelin is metabolized by peptidases, NOT cytochrome P450 enzymes
• Only 80% protein binding (not highly bound)
• No formal drug-drug interaction studies conducted
• Low probability of pharmacokinetic interactions

Safe with Common Medications:

• Antibiotics
• Antihistamines
• NSAIDs
• Proton pump inhibitors
• Statins
• SSRIs (though caution for seizure risk)
• Most other common medications

Administration Timing Interactions:

Nasal Decongestants:

• May reduce nafarelin absorption if used concurrently
• Recommendation: Use decongestant at least 2 hours AFTER Synarel dose
• This allows adequate absorption time

Nasal Corticosteroids:

• May affect absorption if used simultaneously
• Separate administration times recommended

Pharmacodynamic Considerations:

Seizure Threshold-Lowering Drugs:

• Postmarketing reports of convulsions with GnRH agonists
• Use caution with:
  • Bupropion
  • SSRIs
  • Tramadol
  • Certain antipsychotics
• Not a contraindication but monitor closely

QT-Prolonging Medications:

• GnRH agonists may contribute to QT prolongation (class effect)
• Use caution with other QT-prolonging agents
• Consider ECG monitoring if combining

Hormone Preparations:

• Exogenous estrogen or testosterone would counteract nafarelin's effects
• Discontinue hormone therapy before initiating nafarelin
• Exception: Add-back therapy in endometriosis (intentional low-dose estrogen)

Laboratory Test Interference:

• Suppresses LH, FSH, estradiol, testosterone (therapeutic effect)
• No interference with routine chemistry or hematology panels
• Bone age X-rays should show slowed maturation in CPP

8. Contraindications

Absolute Contraindications:

Hypersensitivity:

• Known hypersensitivity to nafarelin, GnRH, or GnRH agonists
• Hypersensitivity to any component of the formulation
• Previous anaphylaxis to GnRH analog

Pregnancy (Category X):

• Contraindicated in pregnancy
• May cause fetal harm
• Pregnancy test required before initiating therapy (endometriosis)
• Advise non-hormonal contraception during treatment

Breastfeeding:

• Not recommended during lactation
• Unknown if excreted in breast milk
• Potential for serious adverse effects in nursing infants

Undiagnosed Vaginal Bleeding:

• Must evaluate before initiating treatment
• Rule out malignancy or other pathology

Relative Contraindications/Precautions:

Nasal Conditions:

• Severe rhinitis may impair drug absorption
• Nasal polyps
• Recent nasal surgery
• Chronic sinusitis
• May need alternative GnRH agonist formulation

Osteoporosis/Bone Density Concerns:

• Pre-existing osteopenia or osteoporosis
• Risk factors for bone loss
• Limit treatment duration
• Consider bone densitometry monitoring

Psychiatric History:

• Depression or mood disorders may be exacerbated
• Particularly important in pediatric patients
• Monitor closely for worsening symptoms
• Rare reports of suicidal ideation in children

Seizure Disorders:

• Reports of convulsions with GnRH agonists
• Use with caution in patients with epilepsy
• Monitor for increased seizure frequency

Cardiovascular Disease:

• QT prolongation possible
• Use caution with other QT-prolonging medications
• Consider ECG monitoring

9. Special Populations

Pediatric Patients (CPP):

• Primary approved indication
• Girls: Treatment begins age 2-8 years typically
• Boys: Treatment begins age 2-9 years typically
• Starting dose: 1600 mcg/day, may increase to 1800 mcg/day
• Continue until appropriate age for natural puberty (11-12 girls, 12-13 boys)
• Monitor for psychiatric symptoms (emotional lability, mood changes)
• Arrest of breast development in 82% of girls
• Arrest of genital development in 100% of boys
• Pubic hair affected in only 54% (adrenal androgen-dependent)
• Effects fully reversible upon discontinuation

Women of Reproductive Age (Endometriosis):

• Approved for women 18 years and older
• Exclude pregnancy before treatment
• Non-hormonal contraception required
• Treatment duration: Maximum 6 months
• Fertility preserved after treatment discontinuation
• May consider add-back therapy to reduce hypoestrogenic symptoms

Adolescents/Transgender Patients:

• Off-label use for puberty suppression in gender dysphoria
• Provides reversible pubertal suppression
• Standard CPP dosing protocols used
• Continue until decision regarding gender-affirming hormones

Geriatric Patients:

• Not typically indicated (postmenopausal women already have low estrogen)
• No specific data in elderly

Renal Impairment:

• No formal pharmacokinetic studies
• Approximately 44-55% renally excreted
• Caution in severe renal impairment
• No specific dose adjustment established

Hepatic Impairment:

• Non-hepatic metabolism (peptidases)
• Likely safe in hepatic dysfunction
• No dose adjustment typically required

Pregnancy:

• Category X: Contraindicated
• Exclude pregnancy before initiation
• Discontinue immediately if pregnancy occurs
• Use non-hormonal contraception during treatment

Lactation:

• Unknown if excreted in breast milk
• Not recommended during breastfeeding
• Discontinue nursing or discontinue drug

10. Monitoring Parameters

Baseline Assessment (Before Treatment):

Central Precocious Puberty:

• Confirmation of CPP diagnosis:
  • Clinical: Secondary sexual characteristics at inappropriate age
  • Hormonal: Pubertal LH, FSH, sex steroids
  • GnRH stimulation test if diagnosis unclear
  • Brain MRI (rule out CNS pathology)
• Bone age X-ray (should show advancement)
• Height, weight, growth velocity calculation
• Tanner staging (pubertal development)
• Predicted adult height assessment

Endometriosis:

• Pregnancy test (mandatory - repeat monthly as needed)
• Baseline symptom assessment (pain severity)
• Consider bone densitometry if treatment may extend
• Baseline estradiol level

Ongoing Monitoring - CPP:

Treatment Response (First 2 Months):

• Resolution of pubertal signs expected
• If inadequate suppression:
  • Assess compliance (critical for nasal spray)
  • Rule out gonadotropin-independent precocity
  • Consider dose increase to 1800 mcg/day

Hormonal Assessment (Every 3-6 Months):

• LH, FSH: Should be suppressed to prepubertal levels
• Testosterone (boys) or estradiol (girls): Should be suppressed
• GnRH stimulation test if breakthrough suspected

Growth Parameters:

• Height and weight: Every 3-6 months
• Growth velocity: Should slow during treatment
• Bone age: Every 6-12 months (advancement should slow)
• Tanner staging: Every visit

Behavioral Monitoring:

• Mood and behavior assessment each visit
• Screen for emotional lability, depression
• Suicide risk awareness (rare but reported)

Ongoing Monitoring - Endometriosis:

Symptoms:

• Pain assessment each visit
• Menstrual status (amenorrhea expected by month 2)
• Quality of life measures

Bone Health:

• Consider DEXA scan if treatment approaches 6 months
• Do not exceed 6 months due to bone density concerns

Treatment Duration:

• Maximum recommended: 6 months
• Reassess at 3-6 months

Discontinuation/End of Treatment:

CPP:

• Remove treatment when appropriate for natural puberty
• Monitor for return of pubertal progression
• Menses should resume, puberty should progress normally
• One-year post-treatment follow-up shows reversal in all patients

Endometriosis:

• Normal function typically returns within 4-8 weeks
• Symptoms may recur after discontinuation
• Not a curative treatment

11. Cost and Availability

Brand Name Product:

Synarel (Pfizer):

• 2 mg/mL nasal spray solution
• Each bottle contains approximately 60 sprays
• AWP (at 1990 approval): $1,410 for 6-month treatment
• Current AWP: ~$1,200-1,500 per bottle (2024)
• Annual cost for CPP (using 1600 mcg/day): ~$15,000-20,000

Generic Availability:

• Generic nafarelin nasal spray available in some markets
• Limited generic availability in United States
• Cost advantage with generics when available

Cost Comparison with Other CPP Treatments:

| Product | Annual Cost | Administration | |------

Goal Relevance:

• I want to manage my endometriosis symptoms and reduce pain.
• I'm looking to stop early puberty in my child to help them grow taller.
• I need a non-injection option for treating my child's central precocious puberty.
• I'm seeking relief from pelvic pain associated with endometriosis.
• I want to reduce the size of endometriotic lesions to improve my quality of life.
• I'm exploring options to delay puberty for my child until the appropriate age.
• I need a treatment that can help with hormone regulation for endometriosis.
• I want to preserve my child's adult height potential by managing early puberty.

---|-------------|----------------| | Synarel (nafarelin) | ~$15,000-20,000 | Nasal spray BID-TID | | Lupron Depot-Ped | ~$15,000-20,000 | IM monthly or q3mo | | Triptodur | ~$25,000 | IM every 6 months | | Supprelin LA | ~$45,000 | SC implant yearly |

Synarel is competitively priced but requires more frequent dosing.

Insurance Coverage:

• Prior authorization typically required
• Documentation of CPP or endometriosis diagnosis needed
• May require step therapy or alternative trial in some plans
• Specialty pharmacy distribution in some cases

Patient Assistance Programs:

• Pfizer Patient Assistance Program available
• Income-based eligibility
• Copay assistance programs
• Endometriosis Association and other advocacy groups may provide resources

Availability:

• Available in United States with prescription
• Also marketed in UK, Europe, Canada, and other regions
• Specialty pharmacies may be required
• Not all local pharmacies stock nasal spray GnRH agonists

12. Clinical Evidence Summary

Central Precocious Puberty:

Pivotal Clinical Trials:

• Demonstrated effective suppression of pubertal development
• Breast development arrested or regressed in 82% of girls
• Genital development arrested or regressed in 100% of boys
• Pubic hair (adrenal androgen-dependent) arrested in only 54%
• Linear growth velocity slowed
• Bone age advancement delayed

Long-Term Follow-up:

• One-year post-treatment follow-up (n=69) showed complete reversal
• Return of menses in girls
• Return of pubertal gonadotropin and sex steroid levels
• Advancement of secondary sexual development resumed
• Adult height outcomes comparable to predicted

Comparison Studies:

• European Society for Paediatric Endocrinology/Lawson Wilkins Society consensus: All GnRH agonists effective despite different routes and dosing
• No significant efficacy differences between nafarelin and injectable agonists
• Choice based on preference for nasal vs. injection

Endometriosis:

FDA Approval Studies:

• First new endometriosis treatment in 14 years at approval
• Rated "1B" by FDA (therapeutic advantages over existing treatments)
• Demonstrated pain relief and lesion size reduction
• Efficacy similar to danazol with better tolerability

Comparative Data:

• Equivalent efficacy to other GnRH agonists (goserelin, leuprolide)
• 400-800 mcg/day regimens effective
• Add-back therapy maintains efficacy while reducing hypoestrogenic symptoms

Limitations:

• Treatment limited to 6 months (bone density concerns)
• Symptoms may recur after discontinuation
• Not curative; palliative treatment

IVF/Assisted Reproduction:

• Effectively suppresses endogenous gonadotropin secretion
• Prevents premature LH surge
• Compatible with FSH stimulation protocols
• Alternative to injectable GnRH agonists for patients preferring nasal route

13. Comparison with Alternatives

GnRH Agonists for CPP:

Key Differentiators for Nafarelin:

Advantages:

1. Non-injection option: Ideal for needle-phobic children
2. Self-administered: No office visits for each dose
3. Room temperature storage: Convenient handling
4. Cost-effective: Lower drug acquisition cost
5. Dose adjustability: Can titrate if needed

Disadvantages:

1. Multiple daily doses: Compliance burden
2. Low bioavailability: Only 2.8% absorbed
3. Nasal conditions: May affect absorption
4. Parent/child dependent: Requires adherence
5. Sneezing/congestion: Can reduce effectiveness

Clinical Decision Factors:

Choose Nafarelin When:

• Child or parent strongly prefers non-injection option
• Good family compliance expected
• No significant nasal conditions
• More frequent clinic visits acceptable for monitoring
• Cost is a significant factor

Choose Injectable GnRH Agonist When:

• Compliance concerns with daily nasal spray
• Chronic nasal conditions present
• Less frequent dosing preferred
• Office-based administration preferred

GnRH Agonists for Endometriosis:

For endometriosis, choice often based on patient preference for home-based nasal spray vs. monthly office injection.

14. Storage and Handling

Storage Requirements:

• Store at room temperature: 15-30°C (59-86°F)
• Protect from light (keep in original carton)
• Store bottle upright
• Do not freeze
• Keep away from excessive heat
• No refrigeration required (advantage over many GnRH agonists)

Handling Instructions:

Before First Use:

1. Remove protective cap
2. Prime pump by pressing down 5-10 times until fine mist appears
3. Priming ensures accurate dose delivery

For Each Dose:

1. Clear nasal passages (blow nose gently if needed)
2. Tilt head slightly forward
3. Insert spray tip into nostril
4. Aim tip away from nasal septum (toward outer wall)
5. Press pump firmly and inhale gently
6. Hold breath briefly
7. Alternate nostrils for subsequent sprays
8. Avoid sneezing during or immediately after dosing
9. Replace protective cap

If Dose Missed:

• Take missed dose as soon as remembered
• If close to next scheduled dose, skip missed dose
• Do not double doses
• Note: Missed doses may reduce suppression effectiveness

Travel Considerations:

• Room temperature storage: Easy travel
• Carry in original packaging
• Protect from extreme temperatures
• TSA allows medically necessary liquids
• Keep accessible (not in checked luggage if possible)

Disposal:

• Dispose of empty bottles in regular trash
• No special hazardous material handling required
• Check local regulations for pharmaceutical waste
• Keep out of reach of children

Special Handling Notes:

• Avoid allowing tip to contact skin or surfaces (contamination)
• If pump becomes clogged, clean with warm water
• Do not use if solution appears discolored or contains particles
• Check expiration date before each use

15. References

1. Pfizer Inc. Synarel (nafarelin acetate) nasal solution Prescribing Information. New York, NY; 2023.

2. FDA Drug Approval Package: Synarel (nafarelin acetate). NDA 019886. February 1990.

3. Citeline. Synarel clears FDA Feb. 13: Syntex' transnasal nafarelin rated "1B" drug for endometriosis. February 1990.

4. Wheeler MD, Styne DM, Kowarski A. Final height in children treated with nafarelin for central precocious puberty. J Pediatr Endocrinol Metab. 1996;9(Suppl 3):355-360.

5. Carel JC, Eugster EA, Rogol A, et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics. 2009;123(4):e752-e762.

6. Pfizer Medical Information. Synarel Clinical Pharmacology. 2024.

7. DrugBank Online. Nafarelin. Accessed December 2024.

8. Medscape. Synarel (nafarelin) dosing, indications, interactions, adverse effects. 2024.

9. DailyMed. Synarel - nafarelin acetate spray, metered. National Library of Medicine. 2024.

10. RxList. Synarel (nafarelin acetate) drug information. 2024.

11. Dlugi AM, Miller JD, Knittle J. Lupron depot (leuprolide acetate for depot suspension) in the treatment of endometriosis: a randomized, placebo-controlled, double-blind study. Fertil Steril. 1990;54(3):419-427.

12. Henzl MR, Corson SL, Moghissi K, et al. Administration of nasal nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial. N Engl J Med. 1988;318(8):485-489.

13. Klein KO, Barnes KM, Jones JV, et al. Increased final height in precocious puberty after long-term treatment with LHRH agonists: the National Institutes of Health experience. J Clin Endocrinol Metab. 2001;86(10):4711-4716.

14. European Society for Paediatric Endocrinology; Lawson Wilkins Pediatric Endocrine Society. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Horm Res. 2009;71 Suppl 1:1-132.

15. Pfizer. Synarel Warnings and Precautions. Pfizer Medical Information. 2024.

Paper completed: December 2024 Research paper for educational and clinical reference purposes

Status: PAPER 64 OF 76 COMPLETE

Next Paper: #65 - Degarelix